全文获取类型
收费全文 | 56335篇 |
免费 | 4621篇 |
国内免费 | 177篇 |
专业分类
耳鼻咽喉 | 511篇 |
儿科学 | 1534篇 |
妇产科学 | 1079篇 |
基础医学 | 7461篇 |
口腔科学 | 961篇 |
临床医学 | 6247篇 |
内科学 | 10801篇 |
皮肤病学 | 809篇 |
神经病学 | 4846篇 |
特种医学 | 2234篇 |
外科学 | 9389篇 |
综合类 | 820篇 |
一般理论 | 57篇 |
预防医学 | 5575篇 |
眼科学 | 1264篇 |
药学 | 4058篇 |
1篇 | |
中国医学 | 53篇 |
肿瘤学 | 3433篇 |
出版年
2023年 | 291篇 |
2022年 | 371篇 |
2021年 | 1156篇 |
2020年 | 658篇 |
2019年 | 1090篇 |
2018年 | 1310篇 |
2017年 | 955篇 |
2016年 | 1028篇 |
2015年 | 1235篇 |
2014年 | 1807篇 |
2013年 | 2504篇 |
2012年 | 3804篇 |
2011年 | 3892篇 |
2010年 | 2119篇 |
2009年 | 1882篇 |
2008年 | 3400篇 |
2007年 | 3658篇 |
2006年 | 3545篇 |
2005年 | 3439篇 |
2004年 | 3185篇 |
2003年 | 3031篇 |
2002年 | 2858篇 |
2001年 | 890篇 |
2000年 | 842篇 |
1999年 | 839篇 |
1998年 | 663篇 |
1997年 | 536篇 |
1996年 | 505篇 |
1995年 | 523篇 |
1994年 | 450篇 |
1993年 | 412篇 |
1992年 | 548篇 |
1991年 | 492篇 |
1990年 | 504篇 |
1989年 | 475篇 |
1988年 | 445篇 |
1987年 | 381篇 |
1986年 | 391篇 |
1985年 | 433篇 |
1984年 | 375篇 |
1983年 | 303篇 |
1982年 | 260篇 |
1981年 | 237篇 |
1980年 | 217篇 |
1979年 | 242篇 |
1978年 | 235篇 |
1977年 | 187篇 |
1974年 | 210篇 |
1973年 | 194篇 |
1972年 | 188篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
991.
992.
Donald R. Dengel Aaron S. Kelly Lei Zhang Qi Wang James S. Hodges Julia Steinberger K. Scott Baker 《Biology of blood and marrow transplantation》2019,25(1):151-156
This study examined the effects of hematopoietic cell transplantation (HCT) and associated preparative regimens on vascular structure and function. Measures of carotid artery stiffness and brachial artery endothelial-dependent dilation were obtained in patients who had survived ≥ 2 years after HCT for hematologic malignancy and were diagnosed at ≤21 years. HCT survivors (n?=?108) were examined: 66 received total body irradiation (TBI) alone or with a low-dose cranial radiation boost (TBI±LD-CRT), 19 received TBI plus high-dose cranial radiation (TBI+HD-CRT), and 23 received a chemotherapy-only preparative regimen (CHEMO). Siblings (n?=?83) were invited to participate as control subjects. Although endothelial-dependent dilation did not differ between siblings and HCT survivors, carotid cross-sectional compliance, cross-sectional distensibility, diameter compliance, and diameter distensibility were greater in siblings than HCT survivors. Comparing the HCT preparative regimens, carotid cross-sectional compliance, cross-sectional distensibility, diameter compliance, diameter distensibility, and incremental elastic modulus were significantly lower in the TBI+HD-CRT group compared with siblings or with TBI±LD-CRT and CHEMO treatment groups. Cross-sectional distensibility and diameter compliance were significantly lower in the TBI±LD-CRT group compared with siblings. TBI±LD-CRT and CHEMO groups did not differ from each other in these vascular measures. HCT preparative regimens containing TBI+HD-CRT resulted in greater arterial decrements, indicating increased risk for cardiovascular disease. 相似文献
993.
994.
995.
Frank?K.?Brown Farida?Kopti Charlie??Chang Scott?A.?Johnson Meir?Glick Chris?L.?Waller 《The AAPS journal》2017,19(5):1255-1263
Merck & Co., Inc., Kenilworth, NJ, USA, is undergoing a transformation in the way that it prosecutes R&D programs. Through the adoption of a “model-driven” culture, enhanced R&D productivity is anticipated, both in the form of decreased attrition at each stage of the process and by providing a rational framework for understanding and learning from the data generated along the way. This new approach focuses on the concept of a “Design Cycle” that makes use of all the data possible, internally and externally, to drive decision-making. These data can take the form of bioactivity, 3D structures, genomics, pathway, PK/PD, safety data, etc. Synthesis of high-quality data into models utilizing both well-established and cutting-edge methods has been shown to yield high confidence predictions to prioritize decision-making and efficiently reposition resources within R&D. The goal is to design an adaptive research operating plan that uses both modeled data and experiments, rather than just testing, to drive project decision-making. To support this emerging culture, an ambitious information management (IT) program has been initiated to implement a harmonized platform to facilitate the construction of cross-domain workflows to enable data-driven decision-making and the construction and validation of predictive models. These goals are achieved through depositing model-ready data, agile persona-driven access to data, a unified cross-domain predictive model lifecycle management platform, and support for flexible scientist-developed workflows that simplify data manipulation and consume model services. The end-to-end nature of the platform, in turn, not only supports but also drives the culture change by enabling scientists to apply predictive sciences throughout their work and over the lifetime of a project. This shift in mindset for both scientists and IT was driven by an early impactful demonstration of the potential benefits of the platform, in which expert-level early discovery predictive models were made available from familiar desktop tools, such as ChemDraw. This was built using a workflow-driven service-oriented architecture (SOA) on top of the rigorous registration of all underlying model entities. 相似文献
996.
997.
998.
999.
1000.
Non-alcoholic fatty liver disease is comprised of either simple steatosis (non-alcoholic fatty liver) or a more advanced inflammatory and fibrogenic stage (non-alcoholic steatohepatitis [NASH]). NASH affects a growing proportion of the global adult and pediatric population, leading to rising rates of liver fibrosis and hepatocellular carcinoma. NASH is a multifactorial disease that is part of a systemic metabolic disorder. Here, we provide an overview of the metabolic underpinnings of NASH pathogenesis and established drivers of inflammation and fibrosis. Clarification of underlying fibrogenic and inflammatory mechanisms will advance the development of novel treatment strategies as there are no approved therapies at present. We discuss emerging experimental approaches and potential novel investigational strategies derived from animal models including the inflammasome, epigenetic reprogramming, Hippo signaling, Notch signaling, engineered T cells to remove fibrogenic HSCs, and HSC-specific targeting therapies. Recently completed and ongoing clinical trials and antifibrotics are discussed, illuminating the growing expectation that one or more therapies will yield clinical benefit in NASH in the coming years. 相似文献